SEP 29, 2026 · JOURNAL ARTICLE
Overcoming EGFR Resistance by Monovalent and Bident Inhibitors Targeting Cys775
Acs Central Science
Abstract Covalent targeting of EGFR cysteine 797 by osimertinib is one of the most successful breakthroughs in targeted therapy, fundamentally transforming the treatment landscape